Oxford BioDynamics Partners with Bupa to Offer EpiSwitch Checkpoint Inhibitor Response Test

Oxford BioDynamics saw a rise in shares following the announcement that customers of Bupa, a leading private health insurer in the UK, will now have access to its innovative smart blood test, the EpiSwitch checkpoint inhibitor response test.

At 0734 GMT, Oxford BioDynamics' shares were up 6.5 pence, representing a 20% increase and reaching 39.5 pence.

In a strategic agreement revealed on Wednesday, the UK biotechnology company stated that this collaboration with Bupa significantly advances the availability of checkpoint inhibitor response tests in the country. The EpiSwitch test has demonstrated remarkable accuracy in predicting how cancer patients will respond to immune checkpoint inhibitor treatment. This breakthrough technology empowers physicians by providing valuable insights for treatment planning and aiding in the navigation of complex decisions.

While immune checkpoint inhibitors have shown promise in controlling diseases for certain patients, they come with high costs, and less than one in four patients experience long-term survival benefits. Furthermore, many patients experience severe illness and require hospitalization. The EpiSwitch test aims to spare individuals from unnecessary side effects caused by treatments that prove ineffective for them, thus revolutionizing patient care.

Jon Burrows, Chief Executive of Oxford BioDynamics, expressed his enthusiasm for this partnership, stating, "Gaining reimbursement from the UK's leading health insurer is another significant achievement for our company. It will greatly benefit Bupa customers and their doctors."